Global Car T Cell Therapy Market Research Report Forecast to 2027

CAR-T Cell Therapy Market Forecast till 2027

Market Overview

The growing market trends and demand are expected to have a positive impact on the market size of CAR-T cell therapy products. CAR-T cell therapy, using re-engineered patient WBCs to identify and combat cancer cells, is a cutting-edge treatment method. CAR-T cell therapy consists of using modified T cells to target and eliminate cancer cells. It consists of three phases: collecting T cells, engineering them, and infusing them into the patient's body. CAR-T cell therapy harnesses the body's immune system to combat cancer. However, cytokine release syndrome (CRS) can occur as a side effect, causing symptoms like fever, fatigue, nausea, low blood pressure, breathing difficulties, and more.

The CAR T therapy industry is expected to experience strong growth in the coming years due to a rising number of cancer cases worldwide. The treatment has gained widespread interest due to its remarkable results and has received approval from the FDA for two treatments in 2017. The growth of the life science and biotechnology sectors, coupled with increasing patient assistance programs and government efforts to raise cancer awareness, will further support the industry's expansion.

Segment Overview
The CAR-T cell therapy market is segmented based on targeted antigens, including BCMA, CD19/CD22, Lewis Y, PSCA, NKR-2, MUC16, ROR1, and others. 

Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma are the primary applications of CAR-T cell therapy, with the Acute Lymphoblastic Leukemia segment expected to see the fastest growth due to heightened awareness of its use in treating acute leukemia and the expected launch of drugs to treat blood cell cancer. The segment's growth will be further driven by an increase in cases of Acute Lymphoblastic Leukemia and support from both public and private organizations.

Regional Analysis
North America leads the CAR-T market since the region has high presence of many life sciences companies working on CAR T-cell development and distribution, as well as advanced quality control systems. 
The Asia Pacific CAR-T therapy market is projected to grow rapidly, attributed to rising awareness, improved healthcare infrastructure, developing business and commercial centers, and increased company investments. Government support through funding and regulations also contributes to growth, such as South Korea passing a law in 2020 to ensure patient safety during clinical trials and strengthen support for regenerative medicine.

Major Players
Key players in the market Cellectis (France), Caribou Biosciences, Inc. (US), Bluebird Bio (US), Noile-Immune Biotech (Japan), Celyad (Belgium), Celgene Corporation (US), Bellicum Pharmaceuticals, Inc. (US), Intellia Therapeutics (US), Novartis International AG (Swiss), Pfizer Inc. (US), Servier Laboratories (France), Mereck KGaA (Germany), and Amgen Inc. (US).

COVID 19 Impacts
The COVID-19 pandemic has had a great impact on the global economy since its emergence in late 2019. The World Health Organization declared it a global health crisis in 2020. The virus has affected the availability of drugs and vaccines, created disruptions in their distribution, and had financial consequences for companies and financial markets. Nationwide lockdowns hindered the transportation of drugs and vaccines in countries such as Saudi Arabia, India, U.A.E., China, and Egypt. The World Health Organization reported that as of November 15, 2022, there were over 632 million confirmed cases of COVID-19 worldwide.

The pandemic also has significant implications for cancer patients receiving CAR-T cell therapy. For example, data published by Duke-NUS, a school of National University of Singapore, in April 2020 indicated that CAR-T cell therapy may be useful for treating SARS-CoV-2 and other infectious diseases.